Clinical efficacy of Nipple-areola complex-sparing mastectomy combined with latissimus dorsi myocutaneous flap Stage Ⅰ breast reconstruction
Objective To investigate the clinical efficacy and safety of Nipple-areola complex-sparing mastectomy combined with latissimus dorsi muscle flap breast reconstruction in the treatment of breast cancer.Methods The clinical data of 47 patients with breast cancer who underwent Nipple-areola complex-sparing mastectomy combined with latissimus dorsi muscle flap simultaneous breast reconstruction in our hospital from January 2023 to June 2024 were retrospectively analyzed.The survival rate of skin flap,the excellent and good rate of surgical results,the incidence of surgical complications and the scores of quality of life instruments for cancer patients-breast cancer before and 3 months after surgery were statistically analyzed.Results The operative time of 47 patients was(192.43±11.87)min,and the intraoperative blood loss was(78.85±8.96)mL.The follow-up showed that all 47 patients with flap were alive,and the rate of excellent and good operation was 93.62％(44/47).The QLQ-BR53 score of 47 patients ranged from(147.63±11.25)points to(68.67±8.57)points at 3 months after operation,with statistical significance(P＜0.001).The complication rate was 12.77％(6/47).Conclusions Nipple-areola complex-sparing mastectomy combined with latissimus dorsi myocutaneous flap simultaneous breast reconstruction has good clinical efficacy in the treatment of breast cancer,which can effectively guarantee the repair effect and improve the postoperative quality of life of patients.
breast cancernipple-areola complex-sparing mastectomylatissimus dorsi myocutaneous flapbreast reconstruction
万方数据
维普
